Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, Australia.
Discipline of Addiction Medicine, Faculty Medicine and Health, University of Sydney, Sydney, Australia.
Drug Alcohol Rev. 2020 May;39(4):356-364. doi: 10.1111/dar.13050. Epub 2020 Mar 4.
The Australian Treatment Outcomes Profile (ATOP) was developed as a clinical tool for monitoring the substance use, health and wellbeing of clients in alcohol and other drug treatment. This is the first psychometric validation of the ATOP in a cannabis-dependent treatment population.
A total of 128 individuals with cannabis dependence enrolled in an outpatient randomised controlled trial were administered the ATOP and gold-standard health and wellbeing questionnaires once by clinicians and once by researchers at baseline. Concurrent validity was assessed by testing ATOP Psychological Health, Physical Health and Quality of Life questions against concurrently administered gold-standard questionnaires: the Short Form 36 Health Survey (SF-36), the 21-item Depression, Anxiety and Stress Scale (DASS-21) and the Sheehan Disability Scale (SDS). Interrater reliability was tested by comparing clinician-administered ATOP items at the medical screening interview to the same ATOP items administered by researchers at baseline.
ATOP Psychological Health showed moderate to strong correlations with SF-36 Mental Components, SF-36 Mental Health and DASS-21 scores (r = 0.40-0.52) and ATOP Physical Health with SF-36 Physical Components and SF-36 General Health scores (r = 0.36-0.67). The ATOP Quality of Life scale showed moderate agreement with the SDS and six-dimensional health state short form scales (r = 0.38-0.40). ATOP substance use, employment, education and child care items showed good to excellent interrater reliability (Krippendorff's α = 0.62-0.81), and tobacco use, Psychological Health, Physical Health and Quality of Life showed fair to moderate interrater reliability (Krippendorff's α = 0.42-0.53).
The ATOP appears to be valid and reliable when tested in a population with cannabis-dependence, justifying its widespread use in clinical settings.
澳大利亚治疗结果概况（ATOP）是作为监测酒精和其他药物治疗中客户的物质使用、健康和福利的临床工具而开发的。这是首次在大麻依赖治疗人群中对 ATOP 进行心理测量验证。
共 128 名大麻依赖患者参加了一项门诊随机对照试验，在基线时由临床医生和研究人员分别为他们进行了 ATOP 和黄金标准健康和福利问卷的评估。同时通过以下方法评估 ATOP 心理卫生、身体健康和生活质量问题的同时效度：同时进行的黄金标准问卷，即 36 项简短健康调查问卷（SF-36）、21 项抑郁、焦虑和压力量表（DASS-21）和 Sheehan 残疾量表（SDS）。通过比较医疗筛查访谈中临床医生管理的 ATOP 项目与研究人员在基线时管理的相同 ATOP 项目，测试了 ATOP 的评定者间信度。
ATOP 心理卫生与 SF-36 心理成分、SF-36 心理健康和 DASS-21 评分（r = 0.40-0.52）呈中度至强相关，ATOP 身体健康与 SF-36 身体成分和 SF-36 一般健康评分（r = 0.36-0.67）呈中度至强相关。ATOP 生活质量量表与 SDS 和六维健康状态简短量表（r = 0.38-0.40）具有中度一致性。ATOP 物质使用、就业、教育和儿童保育项目具有良好至优秀的评定者间信度（Krippendorff 的α= 0.62-0.81），而烟草使用、心理卫生、身体健康和生活质量具有良好至中度的评定者间信度（Krippendorff 的α= 0.42-0.53）。
在大麻依赖人群中进行测试时，ATOP 似乎具有有效性和可靠性，从而证明其在临床环境中广泛使用的合理性。
